{"groups":[{"description":"Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.","id":"FG000","title":"Lisocabtagene Maraleucel (JCAR017)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Other reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"No longer meets eligibility criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Disease-related complications"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"74"}],"comment":"Participants who underwent leukapheresis","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"63"}],"comment":"Participants who completed leukapheresis and continued to lymphodepleting chemotherapy (LDC) treatment period","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"NOT COMPLETED"}],"title":"Pre-Treatment Phase"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Other reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"23"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Did not receive either JAR017 or nonconforming product"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Received nonconforming product"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"63"}],"comment":"Participants who underwent lymphodepleting chemotherapy (LDC) treatment","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"61"}],"type":"Received JCAR017"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"Received Nonconforming Product"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"Did Not Receive Either JAR017 or Nonconforming Product"},{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"comment":"Completed study","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"NOT COMPLETED"}],"title":"Treatment Phase"}],"preAssignmentDetails":"All efficacy and safety analyses were conducted on the JCAR017-treated Analysis Set."}